Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy
Trial Parameters
Brief Summary
The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are: * What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? * How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.
Eligibility Criteria
Inclusion Criteria: 1. Histological diagnosis of non-small cell lung cancer (Stage I-IV, International Association for the Study of Lung Cancer staging eighth edition) 2. Patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment; 3. No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment; 4. Eastern Cooperative Oncology Group (ECOG) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery; 5. At least one measurable lesion (RECIST v1.1). Exclusion Criteria: 1. Patients included in unblinded clinical trials or anti-tumor drug intervention. 2. Radiotherapy or systemic therapy were used for NSCLC patients before the surgery.